58° and Clear
Image
A major manufacturer of insulin, the Paris-based pharma company Sanofi, has instituted a $35 out-of-pocket cost cap for those with commercial insurance. As of Jan. 1, this will allow many Americans who suffer from diabetes to affordably access life-sustaining insulin. Sanofi has cut the list price of its most commonly prescribed insulin by 78%, per CNN.
According to the American Diabetes Association, the cost of insulin has increased by 24% from 2017 to 2022, when adjusted for inflation. This has led many people to ration their medication, which can have disastrous and even fatal consequences.
Sanofi's price cut comes after two other top insulin manufacturers, Eli Lilly and Novo Nordisk, instituted similar caps. This is the result of pressure from medical institutions, patients, and lawmakers.
Novo Nordisk offers a monthly cap of $35 for eligible patients, including the uninsured, and a $99 cap for others, depending on individual insurance coverage. Eli Lilly offers a $35 monthly cap for those with commercial insurance, and a special savings card for those without. Additionally, thanks to 2022’s Inflation Reduction Act, Medicare enrollees also pay no more than $35 per month for the drug. Click below to learn more about the price caps and what this means for diabetes patients.
By Anita Johnson-Brown and Justice |The Los Angeles News
More News from Los Angeles
- News Mix Top News
- Anita Brown's commentary Opinions matter
